The Wilms' tumor gene WT1 is overexpressed in most of human leukemias regardless of disease subtypes. To characterize the expression pattern of WT1 during normal and neoplastic hematopoiesis, we generated a knock-in reporter green fluorescent protein (GFP) mouse (WT1 GFP/ þ ) and assayed for WT1 expression in normal and leukemic hematopoietic cells. In normal hematopoietic cells, WT1 was expressed in none of the long-term (LT) hematopoietic stem cells (HSC) and very few (o1%) of the multipotent progenitor cells. In contrast, in murine leukemias induced by acute myeloid leukemia 1 (AML1)/ ETO þ TEL/PDGFbR or BCR/ABL, WT1 was expressed in 40.5 or 38.9% of immature c-kit þ lin À Sca-1 þ (KLS) cells, which contained a subset, but not all, of transplantable leukemic stem cells (LSCs). WT1 expression was minimal in normal fetal liver HSCs and mobilized HSCs, both of which are stimulated for proliferation. In addition, overexpression of WT1 in HSCs did not result in proliferation or expansion of HSCs and their progeny in vivo. Thus, the mechanism by which expansion of WT1-expressing cells occurs in leukemia remains unclear. Nevertheless, our results demonstrate that the WT1 GFP/ þ mouse is a powerful tool for analyzing WT1-expressing cells, and they highlight the potential of WT1, as a specific therapeutic target that is expressed in LSCs but not in normal HSCs.
Introduction
The Wilms' tumor gene, WT1, was identified as a tumorsuppressor gene that is deleted in patients with Wilms' tumor, a pediatric renal cancer.
1,2 WT1 is overexpressed in nearly all human leukemias, [3] [4] [5] [6] and mutations in WT1 are observed in B15% of acute myeloid leukemia (AML). 7, 8 Several groups have reported that WT1 can be used as a molecular marker to detect minimal residual disease, and elevation of WT1 expression levels can predict relapse. [9] [10] [11] [12] With regard to therapy, WT1 represents a promising therapeutic target for cytotoxic T-cell (CTL)-mediated immunotherapy. Peptide vaccines derived from WT1 protein can induce CTL recognition and killing of WT1-expressing leukemia cells. [13] [14] [15] [16] Our group as well as others have initiated clinical trials using WT1 peptide vaccines to treat leukemia patients, and these studies have shown promising results. [17] [18] [19] Although it is clear that WT1 overexpression occurs frequently in human leukemia, the mechanism of overexpression remains to be determined. WT1 is also expressed in normal immature hematopoietic cells, although the frequency of WT1-expressing cells in normal hematopoietic cells is likely lower than that seen in leukemia cells. We previously reported that only 1.2% of normal human CD34 þ hematopoietic progenitor cells express WT1, and both CD34 þ CD38 À and CD34 þ CD38 þ bone marrow (BM) cells contain WT1-expressing cells at similar frequencies. 20 However, it remains to be determined what specific subsets of cells express WT1 in normal hematopoietic cells and leukemia cells.
To address this issue, we generated a knock-in green fluorescent protein (GFP)-reporter mouse (WT1 GFP/ þ ), in which GFP was expressed under the endogenous transcriptional regulatory elements of the WT1 gene. Using these WT1 GFP/ þ mice, we examined WT1 expression in normal hematopoietic precursors and leukemic cells from mouse leukemia models.
Materials and methods

Generation of WT1-GFP-knock-in mice
To generate WT1 GFP/ þ mice, 5.5-and 1.5-kb fragments flanking the WT1 ORF were cloned by PCR from genomic DNA of D3 ES cells as 5 0 and 3 0 homologous arms to prepare the targeting vector. The enhanced green fluorescent protein (EGFP) gene was fused in-frame to the ATG of the WT1 translation start site in the 5 0 homologous arm. The resulting 5 0 and 3 0 arms were inserted into 5 0 and 3 0 multiple-cloning sites of the PPNT vector (a kind gift from Dr Tybulewicz, NRC National Institute for Medical Research, UK) to construct the targeting vector ( Figure 1a ). Targeted ES cell clones were obtained by homologous recombination in D3 ES cells. Targeted clones were identified by southern blot analysis with the flanking 5 0 probes (Figure 1b ) and by PCR for the 3 0 arm (Figure 1c ). The targeted ES cells were injected into blastocysts of C57BL/6 mice to obtain chimeric founders. The obtained WT1 GFP/ þ heterozygotes were backcrossed with C57BL/6-CD45.2 mice. Mice were bred and maintained at Stanford University under animal ethics guidelines.
Quantitative RT-PCR analysis
Quantitative RT-PCR analysis was performed with SYBR Green on an ABI 7700 real-time PCR machine (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's protocols. WT1 expression levels were normalized to b-actin expression levels. Primer sequences are available on request.
Immunophenotype analysis
Single-cell suspensions from BM, spleen or fetal liver were treated with ACK for 3 min on ice to lyse erythrocytes, washed with PBS containing 2% FCS, incubated with 20 mg/ml Rat IgG for 20 min to prevent nonspecific antibody binding, and stained with the indicated fluorochrome-conjugated antibodies for 30 min on ice. Cells were then washed and resuspended in 1 mg/ml propidium iodide (PI). CD3, CD4. CD5, CD8, B220, Ter119, Gr-1 and Mac-1 were used as lineage markers. Analysis was performed on a Diva-FACS Vantage equipped with a 488 nm argon laser and a 599 nm dye laser, (Becton Dickinson Immunocytometry Systems (BD), San Diego, CA, USA).
Cell cycle analysis
Cells were incubated in staining medium (Hank's buffered salt solution (HBSS) with 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) and 2% fetal bovine serum (FBS)) containing Hoechst 33342 (5 mg/ml) at 371C for 60 min. After washing, cell surface markers were stained with fluorochrome-labeled mAbs and cells resuspended in 1 mg/ml PI. Analysis was performed on a FACSAria equipped with a UV laser (Becton Dickinson).
Colony-forming assay
Cells were seeded in M3434 methylcellulose medium (Stem Cell Technologies, Vancouver, BC, Canada) containing 10 mg/ml each of stem cell factor (SCF), FMS-like tyrosine kinase 3 ligand (Flt3L), interleukin 11 (IL11), thrombopoietin (TPO), interleukin 3 (IL3), granulocyte-monocyte colony-stimulating factor (GM-CSF) and 2 U/ml of erythropoietin (Epo) (R&D Systems, Minneapolis, MN, USA). Colony numbers were enumerated on day 14 of culture.
Induction of leukemia using BM cells
Retrovirus was produced by transfection of Phoenix-E (a kind gift from Dr Gary Nolan, Stanford University) or Plat-E (a kind gift from Dr Toshio Kitamura, Tokyo University, Japan) producer cells. BM cells from WT1 GFP/ þ mice treated with 150 mg/kg of 5-fluorouracil were harvested at 5 days postinjection and cultured in Iscove's modified Dulbecco's medium (IMDM) containing 5% FBS, 10 ng/ml SCF (R&D Systems), 10 ng/ml Flt3L and 10 ng/ml IL11 for 24 h. Cultured cells were infected with MSCV-TEL/PDGFbR-IRES-AML1/ETO (a kind gift from Dr Michael Thomasson, Washington University) or MSCVp210BCR/ABL-Neo (a kind gift from Dr Warren Pear, University of Pennsylvania) retrovirus for 24 h in the presence of 4 mg/ml of polybrene. Transduced cells were transplanted into lethally irradiated C57BL/6-CD45.1 recipient mice (2-5 Â 10 5 cells per mouse).
Lentivirus transduction and transplantation
was cloned upstream of an internal ribosome entry site (IRES)/ EGFP sequence into a self-inactivating lentiviral vector plasmid, pRRL.sin18. PPT.PGK.IRES.GFP. Viral stocks were produced by cotransfection of 293T cells along with a plasmid encoding the lentiviral gag-pol proteins and a plasmid encoding the vesicular somatitis virus G glycoprotein. Lentivirus-containing supernatant medium was concentrated by ultracentrifugation. The titers of viruses expressing WT1-A and WT1-B were similar to those of empty vector (B5 Â 10 7 cfu/ml). Hematopoietic stem cells (HSCs; c-kit 
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N Hosen et al from C57BL/6-CD45.2 mice and cultured in 200 ml with concentrated viral stocks (1:100 dilution) in IMDM containing 5% FCS, 50 mM 2-mercaptoethanol, SCF (10 ng/ml), Flt3L (10 ng/ml), IL11 (10 ng/ml) for 12 h at 371C. Transduced HSCs (2000 HSCs/mouse) were mixed with a radioprotective dose of 2.5 Â 10 5 clongenic Sca-1 þ cell-depleted CD45.1 helper BM cells and transplanted into lethally irradiated (950 rad), congenic C57BL/6-CD45.1 recipients.
Results
Generation of WT1-GFP-knock-in mice
To produce WT1 reporter (WT1 GFP/ þ ) mice, GFP was used to replace exon1 of the WT1 gene through homologous recombination (Figure 1a-c) . This knock-in allele contains identical transcriptional regulatory elements to the wild-type allele, but the transcribed messenger RNA (mRNA) encodes GFP rather than WT1. The WT1 GFP/ þ mice were indistinguishable with respect to hematopoietic cellularity and lineage composition from wild-type littermates ( Figure 1d ). In addition, loss of a single WT1 allele did not affect viability, and heterozygote WT1 GFP/ þ Â WT1 GFP/ þ matings consistently yielded litters composed of WT1 GFP/ þ and WT1 þ / þ mice in a 2:1 ratio, consistent with Mendelian segregation and the previously reported lethality of WT1 GFP/GFP homozygotes.
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To confirm the validity of our reporter system, we examined the correlation between GFP expression and WT1 expression in WT1 GFP/ þ mice. We used fluorescence-activated cell sorting (FACS) to fractionate lineage marker-negative (lin À ) BM cells into GFP þ and GFP À populations. The FACS-isolated cells were assayed for WT1 expression by RT-PCR, demonstrating that WT1 expression was detected only in the GFP þ populations but not in the GFP À fraction (Figure 1e ).
WT1 is not expressed in long-term (LT)-HSCs in normal adult BM
Using flow cytometry assay for GFP, we evaluated WT1 expression in different hematopoietic cell populations from the BM and spleen of WT1 GFP/ þ mice (Figure 2a and b). In the
fraction, which is highly enriched for LT-HSCs, 23 essentially no WT1-expressing cells were detected. Similarly, in the Flk2 þ KLS fraction, which is enriched for short-term (ST)-HSCs and multi-potent progenitor cells, 23 only rare WT1-expressing cells were identified (0.8470.39%). In contrast, the frequencies of WT1-expressing cells in common myeloid progenitor (CMP) cells, granulocyte-monocyte progenitor (GMP) cells and megakaryocyte-erythroid progenitor (MEPs) cells 24 (Figure 2c ), indicating that more WT1 þ myeloid progenitor cells are in cell cycle than WT1 À myeloid progenitors. Next, we performed a colony-forming assay on methylcellulose medium to compare the lineage potential of WT1 þ and WT1 À CMP. GEMM, granulocyte-monocyte (GM), granulocyte (G), monocyte (M) and erythroid colonies were all produced from both populations, although the plating efficiencies were much lower from the WT1 þ CMP population compared to the WT1 À CMP population (Figure 2d ). This indicates that WT1 þ myeloid progenitor cells contain functional CMP cells, although their frequency is very low.
WT1 is overexpressed in KLS cells in a mouse myeloid leukemia model induced by TEL/PDGFbR þ AML1/ETO
Given that WT1 is frequently overexpresssed in human leukemias, we tested whether WT1 is also expressed in a previously characterized murine model for myeloid leukemia induced by TEL/PDGFbR þ AML1/ETO 25 ( Figure 3a) . Whole BM cells from the WT1 GFP/ þ mice treated with 5-fluorouracil (5-FU) were transduced with a retrovirus expressing both TEL/PDGFbR and AML1/ETO. Transduced BM cells were transplanted into lethally irradiated recipients, and transplanted mice developed leukemia between 35 and 52 days post transplant. All diseased mice exhibited severe anemia, increased numbers of immature myeloid cells and massive splenomegaly, similar to previous descriptions of this model (Figure 3b ).
Compared to normal WT1 GFP/ þ mice, BM cells from transduced WT1
GFP/ þ mice showed a significant increase in WT1 expression as assayed by GFP. Within the lineage-negative (lin À ) fraction, 13.977.9% of cells from transduced mice versus 4.171.3% of cells from nontransduced mice showed expression of WT1 (n ¼ 3) (Figure 3c and d) (Figure 3c and d) . Thus, similar to human leukemia, WT1 is overexpressed in two mouse leukemia models. Furthermore, WT1 expression was detected in immature KLS cells in both mouse models, while only rare normal KLS BM cells express WT1. To examine whether WT1 is expressed in LSCs, BM cells from mice with leukemia induced by TEL/PDGFbR þ AML1/ETO were separated by FACS into WT1-expressing and -nonexpressing fractions, and these subpopulations were transplanted into sublethally irradiated, RAG2
À/À cytokine receptor common g chain (gc) À/À mice 28 ( 
WT1 is not a surrogate marker of proliferation of HSCs
On the basis of the observation that leukemia cells as well as immature hematopoietic progenitor cells express WT1, it was previously suggested that WT1 expression is a surrogate marker for hematopoietic cell proliferation. 29 (Figure 4a ). Next, we analyzed WT1 expression in HSCs mobilized by injection of cyclophosphamide (Cy) and granulocyte-colony stimulating factor (G-CSF). BM cells were analyzed 3 days after injection of Cy, when many BM HSCs have entered the cell cycle. 31 WT1 expression was observed in only 0.27% of Flk2 À KLS cells (Figure 4b) . Finally, WT1 expression in KLS cells was not induced following in vitro culture with SCF, FLT3L and IL11 (Figure 4c) . Collectively, these results show that WT1 expression in normal HSCs does not occur during proliferative conditions.
Enforced WT1 expression in HSC does not expand HSC or their progeny
Since WT1 expression was observed in immature leukemic KLS cells but not in normal HSCs, we reasoned that WT1 may exert an oncogenic effect when ectopically expressed in HSCs. To test this hypothesis, we assessed the effect of enforced WT1 expression in HSCs. We constructed two recombinant lentiviruses that express either WT1-A or WT1-B, which represent two of the four major WT1 splice variants. 21 Highly purified 32 were transduced with either a recombinant WT1-expressing lentivirus or an empty vector and transplanted into lethally irradiated congenic mice along with a radio-protective dose of helper BM cells (Figure 5a and b) . Twelve weeks after transplant, the percen- GFP/ þ mice i.p. on day 0, and then granulocytecolony stimulating factor (G-CSF; 250 mg/kg) was subcutaneously injected daily beginning on day 1. BM cells were analyzed at day 3 and GFP expression in Flk2 (Figure 5d and e). The frequencies of GFP þ common lymphoid progenitor (CLP), CMP, GMP, MEP, granulocytes, B lymphocytes in BM or T lymphocytes in the spleen were also significantly lower in mice transplanted with WT1-A or WT1-Btransduced HSCs compared with those in GFP control mice (Figure 5d and e) . These results indicate that WT1 expression in HSCs does not promote the proliferation or expansion of HSCs or their progeny. In addition, abnormal accumulation of HSCs or progenitor cells through a block in differentiation was not observed in GFP þ BM cells, indicating that cell differentiation was not impaired by WT1 expression (Figure 5d ). Collectively, these findings show that WT1 expression itself does not confer a competitive advantage to HSCs or progenitor cells.
Discussion
Here, we report the generation of a novel WT1-GFP knock-in reporter mouse, which allows for the identification and isolation of viable WT1-expressing cells. This mouse represents a useful tool for leukemia research as well as other types of malignancies, since WT1 is overexpressed in many different types of cancer. 33, 34 In addition, the GFP-reporter system will aid studies to understand the role of WT1 in normal development of kidney, 22 genital system 35 or other tissues 36, 37 in which WT1 has an important role. Although Hastie and colleagues 38 previously generated WT1-LacZ reporter transgenic mice, a technically challenging staining procedure is necessary to isolate viable WT1-expressing cells. 39 In this study, we used GFP to isolate viable WT1-expressing cells that have fully functional in vivo activity in transplantation experiments.
Our results demonstrate that WT1 is expressed at detectable levels in none of mouse LT-HSCs, and only rare multipotent progenitor cells, and so is not a component of the normal phenotype of these cells. Previous reports have shown that WT1-deficient fetal liver HSCs can repopulate lethally irradiated mice, 40 consistent with the lack of its expression on HSCs. In contrast, our results show that WT1 is expressed in the immature (KLS) population of mouse leukemia induced by TEL/ PDGFbR þ AML1/ETO or p210 BCR/ABL. Furthermore, in leukemia induced by TEL/PDGFbR þ AML1/ETO, WT1-expressing KLS leukemia cells contain transplantable LSCs. Several studies on human primary AML samples showed that LSCs shared some cell surface markers with normal HSCs (CD34 þ CD38 À ), 41 although subsequent studies indicated that LSCs were CD90 À , whereas normal HSCs are CD90 þ . [42] [43] [44] We previously reported that WT1 was expressed at very high levels in the CD34
þ CD38 À population of human AML cells. 45 Collectively, these studies along with our current findings suggest that WT1 may be a potentially useful therapeutic target for LSC-specific immunotherapy. We have already finished a phase I clinical trial for a WT1-peptide vaccine therapy, and some patients with AML or myelodysplastic syndrome (MDS) have shown a response to this treatment. 17 Interestingly, one MDS patient with a relatively low level of overall WT1 expression showed a dramatic clinical improvement. 18 The reason for this finding is unclear, although it is possible that WT1 may be specifically expressed in rare MDS-stem cells.
Although the specificity of WT1 expression in leukemic versus normal hematopoietic cells suggests that it may be an attractive potential therapeutic target, our transplantation experiments showed that some LSCs do not express WT1, and therefore, it is conceivable that WT1-negative leukemic cells may emerge during immunotherapy. Such a result would indicate that it would be wise to target other molecules in combination with WT1 to eradicate leukemia cells completely. Therefore, it is important to identify additional therapeutic targets like WT1 that are expressed on LSCs but not on normal HSCs.
The mechanism by which WT1 overexpression occurs in human or mouse immature leukemia cells remains to be determined. Our data clearly show that enforced expression of WT1 in normal HSC does not lead to increased numbers of HSC or their progeny in vivo. This result is compatible with previous reports from two other groups using human HSCs and progenitor cells. Gullberg and colleagues 46 demonstrated that WT1-A or WT1-B expression in human CD34 þ hematopoietic cells resulted in inhibition of proliferation. Haber and colleagues 47 reported that expression of WT1-B, and to a lesser extent WT1-A, in human CD34 þ CD38 À immature hematopoietic cells induced quiescence, and both WT1-A and WT1-B induced differentiation in myeloid progenitor cells. Collectively, these results indicate that WT1 expression by itself does not confer a competitive advantage to HSCs or progenitors, and that the increase of WT1-expressing cells in leukemias are induced by some oncogenic event(s) or by a synergistic effect of WT1 and an oncogene, as was observed between WT1 and AML1/ETO in our previous study. 48 
